No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / ...

The FDA is seeking feedback on whether — and how — to expand the number of men prescribed testosterone treatment.

Despite the absence of separate production data for generic medicines, the total value of medicines produced in India surged ...

Reframing women’s health care includes a greater emphasis on health span, and a closer look at ovarian aging, according to an ...

Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) ...

Explore how nursing students develop clinical judgment through theory, simulation, reflection, and practice, and where a nursing paper writing service fits in.

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

Sulthiame reduced breathing interruptions in sleep apnea patients, pointing toward a viable drug treatment. A European ...

Mandatory QR codes/barcodes on the top 300 drug brands and all active pharmaceutical ingredients (APIs) for end-to-end ...

(the "Company"), a specialty pharmaceutical company focused on combinatorial drug development for cardiovascular diseases, is seeking applications for secondary analyses of existing datasets to ...

This collection is a collaboration between Frontiers in Drug Delivery and Frontiers’ flagship journal, Frontiers for Young Minds, an award‑winning, ...